Large Insider Purchases
Institutional-Scale SEC Form 4 Buy Signals
The Signal of $1M+ Conviction
When a corporate executive invests more than $1,000,000 of their own capital into company shares, it represents the highest level of conviction. These seven-figure purchases reflect management's belief in the company's future value.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-07-02 01:04 | 2020-06-29 | CLR | N/A | Hamm Harold | Director, Officer, 10% owner - Executive Chairman | Other | BUY | $16.70 | 3,135,425 | $52,374,139 | 9,613,820 | +48.4% |
| 2020-07-02 00:27 | 2020-06-30 | AKUS | N/A | BASKETT FOREST | 10% owner | Other | BUY | $17.00 | 588,235 | $9,999,995 | 4,294,207 | +15.9% |
| 2020-07-02 00:38 | 2020-06-30 | AKUS | N/A | SANDELL SCOTT D | 10% owner | Other | BUY | $17.00 | 588,235 | $9,999,995 | 4,294,207 | +15.9% |
| 2020-07-02 00:36 | 2020-06-30 | AKUS | N/A | MAKOWER JOSHUA | 10% owner | Other | BUY | $17.00 | 588,235 | $9,999,995 | 4,294,207 | +15.9% |
| 2020-07-02 00:24 | 2020-06-29 | EVLO | Evelo Biosciences Inc. | Flagship Ventures Fund IV General Partner LLC | 10% owner | Pharmaceutical Preparations | BUY | $3.75 | 4,666,666 | $17,499,998 | 4,079,032 | +100.0% |
| 2020-07-02 04:03 | 2020-06-29 | SRT | N/A | CSP Management Ltd | Director, 10% owner | Other | BUY | $4.86 | 1,543,210 | $7,500,001 | 1,543,210 | +100.0% |
| 2020-06-30 23:35 | 2020-06-26 | N/A | Morgan Stanley Direct Lending Fund | MS Credit Partners Holdings Inc. | 10% owner | Other | BUY | $19.44 | 114,696 | $2,229,697 | 1,166,885 | +10.9% |
| 2020-06-30 03:16 | 2020-06-25 | STLY | HG Holdings, Inc. | Hale Partnership Capital Management, LLC | 10% owner | Real Estate Investment Trusts | BUY | $0.65 | 3,461,011 | $2,249,657 | 362,947 | +100.0% |
| 2020-06-30 23:14 | 2020-06-26 | FRG | N/A | B. Riley Financial, Inc. | 10% owner | Other | BUY | $22.65 | 75,000 | $1,698,435 | 676,471 | +12.5% |
| 2020-06-30 03:20 | 2020-06-25 | CLR | N/A | Hamm Harold | Director, Officer, 10% owner - Executive Chairman | Other | BUY | $16.11 | 1,300,000 | $20,937,280 | 6,478,395 | +25.1% |
| 2020-06-30 02:27 | 2020-06-09 | SONM | DNA X, Inc. | B. Riley Financial, Inc. | Director, 10% owner | Telephone & Telegraph Apparatus | BUY | $0.75 | 1,966,667 | $1,475,000 | 146,666 | +100.0% |
| 2020-07-01 03:29 | 2020-06-26 | TMUS | T-Mobile US, Inc. | FISHER RONALD D | Director, Other | Radiotelephone Communications | BUY | $103.00 | 350,000 | $36,050,000 | 350,000 | +100.0% |
| 2020-07-01 00:37 | 2020-06-26 | TBIO | N/A | BAUPOST GROUP LLC/MA | 10% owner | Other | BUY | $22.00 | 500,000 | $11,000,000 | 18,044,239 | +2.8% |
| 2020-06-30 02:11 | 2020-06-25 | CATM | N/A | Hudson Executive Capital LP | Director, 10% owner | Other | BUY | $23.14 | 270,000 | $6,247,071 | 8,644,880 | +3.2% |
| 2020-06-30 02:36 | 2020-06-29 | NK | ImmunityBio, Inc. | SOON-SHIONG PATRICK | Director, Officer, 10% owner - Chairman and CEO | Biological Products, (No Diagnostic Substances) | BUY | $12.12 | 3,710,000 | $44,965,200 | 23,750,750 | +18.5% |
| 2020-06-30 02:23 | 2020-05-27 | PSTI | Pluri Inc. | CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP | 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $7.61 | 700,449 | $5,328,105 | 3,211,760 | +27.9% |
| 2020-06-27 01:47 | 2020-06-26 | APDN | BNB PLUS CORP. | Montgomery William W | Other | Services-Testing Laboratories | BUY | $6.68 | 190,000 | $1,269,504 | 245,000 | +345.5% |
| 2020-06-26 20:56 | 2020-06-25 | BCPL | N/A | Forethought Life Insurance Co | 10% owner | Other | BUY | $24.26 | 127,782 | $3,100,000 | 338,337 | +60.7% |
| 2020-06-27 00:01 | 2020-06-01 | N-A | N/A | Partners Group Private Equity II, LLC | Other | Other | BUY | $5.89 | 4,241,746 | $25,000,000 | 9,112,844 | +87.1% |
| 2020-06-27 00:46 | 2020-06-24 | BSIG | Acadian Asset Management Inc. | Paulson John | Director, 10% owner | Investment Advice | BUY | $9.79 | 647,263 | $6,336,705 | 20,647,815 | +3.2% |
| 2020-06-27 01:01 | 2020-06-24 | BSIG | Acadian Asset Management Inc. | PAULSON & CO. INC. | 10% owner | Investment Advice | BUY | $9.79 | 647,263 | $6,336,705 | 20,647,815 | +3.2% |
| 2020-06-27 02:49 | 2020-06-26 | SLNO | SOLENO THERAPEUTICS INC | SCHULER JACK W | 10% owner | Pharmaceutical Preparations | BUY | $1.65 | 7,575,759 | $12,500,002 | 4,157,042 | +100.0% |
| 2020-06-27 02:27 | 2019-10-25 | SLNO | SOLENO THERAPEUTICS INC | SCHULER JACK W | 10% owner | Pharmaceutical Preparations | BUY | $1.20 | 2,563,750 | $3,076,500 | 6,217,345 | +70.2% |
| 2020-06-27 02:14 | 2019-03-21 | SLNO | SOLENO THERAPEUTICS INC | SCHULER JACK W | 10% owner | Pharmaceutical Preparations | BUY | $2.14 | 835,717 | $1,784,590 | 835,717 | +100.0% |
| 2020-06-26 02:40 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | Versant Vantage I, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $20.00 | 250,000 | $5,000,000 | 3,419,451 | +7.9% |
| 2020-06-26 02:09 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | Jerel Davis | Director | Pharmaceutical Preparations | BUY | $20.00 | 250,000 | $5,000,000 | 3,419,451 | +7.9% |
| 2020-06-26 01:46 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | Versant Ventures V, LLC | 10% owner | Pharmaceutical Preparations | BUY | $20.00 | 250,000 | $5,000,000 | 3,419,451 | +7.9% |
| 2020-06-26 00:54 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | Bonita David P | Director | Pharmaceutical Preparations | BUY | $20.00 | 774,200 | $15,484,000 | 99,200 | +100.0% |
| 2020-06-25 23:18 | 2020-06-23 | PROG | N/A | Athyrium Opportunities Fund (A) LP | 10% owner | Other | BUY | $15.00 | 3,333,333 | $49,999,995 | 23,303,346 | +16.7% |
| 2020-06-26 00:48 | 2020-06-23 | FMTX | N/A | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% owner | Other | BUY | $20.00 | 1,000,000 | $20,000,000 | 2,252,913 | +79.8% |
| 2020-06-25 19:34 | 2020-06-23 | SSSS | SURO CAPITAL CORP. | Birch Robert S. | 10% owner | Other | BUY | $8.60 | 129,000 | $1,109,284 | 2,825,176 | +4.8% |
| 2020-06-25 23:32 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | Foley Todd | Director | Pharmaceutical Preparations | BUY | $20.00 | 250,000 | $5,000,000 | 3,003,772 | +9.1% |
| 2020-06-25 23:25 | 2020-06-23 | PROG | N/A | Athyrium Capital Management, LP | 10% owner | Other | BUY | $15.00 | 3,333,333 | $49,999,995 | 23,303,346 | +16.7% |
| 2020-06-25 23:31 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | MPM BioVentures 2014, L.P. | 10% owner | Pharmaceutical Preparations | BUY | $20.00 | 250,000 | $5,000,000 | 3,003,772 | +9.1% |
| 2020-06-25 23:33 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | GADICKE ANSBERT | 10% owner | Pharmaceutical Preparations | BUY | $20.00 | 500,000 | $10,000,000 | 5,392,109 | +10.2% |
| 2020-06-26 00:53 | 2020-06-23 | RPTX | Repare Therapeutics Inc. | ORBIMED ADVISORS LLC | Director | Pharmaceutical Preparations | BUY | $20.00 | 774,200 | $15,484,000 | 99,200 | +100.0% |
| 2020-06-24 22:15 | 2020-06-22 | LCRDX | Lord Abbett Credit Opportunities Fund | Christina Seix Dow 2012 Trust | 10% owner | Other | BUY | $9.11 | 384,193 | $3,500,000 | 3,303,295 | +13.2% |
| 2020-06-24 22:13 | 2020-06-22 | LCRDX | Lord Abbett Credit Opportunities Fund | Christina & Robert Dow Foundation | 10% owner | Other | BUY | $9.11 | 658,617 | $6,000,000 | 3,087,606 | +27.1% |
| 2020-06-25 04:19 | 2020-06-23 | FMTX | N/A | Kolchinsky Peter | Director, 10% owner | Other | BUY | $20.00 | 4,000,000 | $80,000,000 | 9,011,651 | +79.8% |
| 2020-06-25 02:46 | 2020-06-22 | CLR | N/A | Hamm Harold | Director, Officer, 10% owner - Executive Chairman | Other | BUY | $16.62 | 3,436,264 | $57,117,924 | 5,178,395 | +197.2% |
| 2020-06-25 04:20 | 2020-06-23 | FMTX | N/A | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Other | BUY | $20.00 | 4,000,000 | $80,000,000 | 9,011,651 | +79.8% |
| 2020-06-25 02:00 | 2020-06-22 | LPTX | CYPHERPUNK TECHNOLOGIES INC. | PERCEPTIVE ADVISORS LLC | 10% owner | Pharmaceutical Preparations | BUY | $2.00 | 1,750,000 | $3,500,000 | 8,476,496 | +26.0% |
| 2020-06-24 04:13 | 2020-06-18 | RPRX | Royalty Pharma plc | Hite Christopher | Officer - EVP & Vice Chairman | Pharmaceutical Preparations | BUY | $28.00 | 70,000 | $1,960,000 | 70,000 | +100.0% |
| 2020-06-24 04:38 | 2020-06-19 | N/A | Compass Therapeutics, Inc. | Sunderland Julie | Director | Biological Products, (No Diagnostic Substances) | BUY | $5.00 | 289,118 | $1,445,590 | 2,502,025 | +13.1% |
| 2020-06-24 04:37 | 2020-06-19 | N/A | Compass Therapeutics, Inc. | Ferneau Philip | Director | Biological Products, (No Diagnostic Substances) | BUY | $5.00 | 314,066 | $1,570,330 | 400,280 | +364.3% |
| 2020-06-24 00:30 | 2020-06-19 | STLY | HG Holdings, Inc. | Hale Partnership Capital Management, LLC | 10% owner | Real Estate Investment Trusts | BUY | $0.65 | 3,685,366 | $2,395,488 | 304,337 | +100.0% |
| 2020-06-24 01:10 | 2020-06-19 | CATM | N/A | Hudson Executive Capital LP | Director, 10% owner | Other | BUY | $23.96 | 208,924 | $5,005,025 | 8,374,880 | +2.6% |
| 2020-06-24 04:37 | 2020-06-19 | N/A | Compass Therapeutics, Inc. | GORDON CARL L | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.00 | 1,455,132 | $7,275,660 | 12,714,404 | +12.9% |
| 2020-06-24 00:12 | 2020-06-20 | FOX | Fox Corp | MURDOCH LACHLAN K | Director, Officer - Executive Chairman, CEO | Television Broadcasting Stations | BUY | $28.32 | 49,498 | $1,401,783 | 302,426 | +19.6% |
| 2020-06-24 04:36 | 2020-06-19 | N/A | Compass Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director, 10% owner | Biological Products, (No Diagnostic Substances) | BUY | $5.00 | 1,455,132 | $7,275,660 | 12,714,404 | +12.9% |
Institutional Conviction in Form 4
Tracking these institutional-scale purchases allows you to follow the "smart money" when their conviction is highest. When an executive or a 10% beneficial owner commits a seven-figure sum to an open-market transaction, it bypasses the routine noise of stock-based compensation. These trades are often a precursor to major corporate developments or a signal that management views the current market valuation as significantly disconnected from the company’s internal growth trajectory. By monitoring these high-value entries, investors can align their portfolios with the capital of those who possess the most intimate understanding of a business's long-term health and potential.
Filtering the Market Noise
Our platform is designed to eliminate the noise and focus strictly on high-impact accumulation from directors and CEOs betting big on their company’s future. The SEC EDGAR database is frequently flooded with thousands of automated Form 4 filings, many of which involve small, technical, or pre-scheduled trades that offer little predictive value for the average investor. By applying a strict $1,000,000 minimum threshold, we isolate the transactions where insiders are taking substantial personal financial risk. This high-conviction filter serves as a powerful transparency tool, identifying the exact moments when corporate leadership moves away from passive ownership toward aggressive capital deployment.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.